Literature DB >> 35865854

Factors associated with death in COVID-19 patients over 60 years of age at Kinshasa University Hospital, Democratic Republic of Congo (DRC).

Ben Bepouka1, Madone Mandina1, Murielle Longokolo1, Nadine Mayasi1, Ossam Odio1, Donat Mangala1, Yves Mafuta1, Jean Robert Makulo2, Marcel Mbula1, Jean Marie Kayembe3, Hippolyte Situakibanza1.   

Abstract

Introduction: the objectives of the present study were to determine the mortality rate in patients over 60 years of age with COVID-19 and to identify risk factors.
Methods: the present historical cohort study took place at the Kinshasa University Hospital (KUH), DRC. Older patients admitted from March 2020 to May 2021 and diagnosed COVID-19 positive at the laboratory were selected. The relationship between clinical and biological risk factors, treatment, and in-hospital mortality was modeled using Cox regression.
Results: of two hundred and twenty-two patients at least 60 years old, 97 died, for a mortality rate of 43.69%. The median age was 70 years (64-74) with extremes of 60 to 88 years. Low oxygen saturation of < 90% (aHR 1.69; 95% CI [1.03-2.77]; p=0.038) was an independent predictor of mortality. The risk of death was reduced with corticosteroid use (aHR 0.54; 95% CI [0.40-0.75]; p=0.01) and anticoagulant treatment (aHR 0.53; 95% CI [0.38-0.73]; p=0.01).
Conclusion: mortality was high in seniors during COVID-19 and low oxygen saturation on admission was a risk factor for mortality. Corticosteroid therapy and anticoagulation were protective factors. These should be considered in management to reduce mortality. Copyright: Ben Bepouka et al.

Entities:  

Keywords:  COVID-19; Democratic Republic of Congo; Kinshasa; advanced age; mortality; risk factors

Mesh:

Substances:

Year:  2022        PMID: 35865854      PMCID: PMC9268318          DOI: 10.11604/pamj.2022.41.330.32602

Source DB:  PubMed          Journal:  Pan Afr Med J


  38 in total

Review 1.  Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections.

Authors:  Petra Zimmermann; Nigel Curtis
Journal:  Arch Dis Child       Date:  2020-12-01       Impact factor: 3.791

2.  Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy.

Authors:  Ning Tang; Huan Bai; Xing Chen; Jiale Gong; Dengju Li; Ziyong Sun
Journal:  J Thromb Haemost       Date:  2020-04-27       Impact factor: 5.824

3.  Clinical characteristics of COVID-19 patients hospitalized at Clinique Ngaliema, a public hospital in Kinshasa, in the Democratic Republic of Congo: A retrospective cohort study.

Authors:  Junior Rika Matangila; Ritha Kibambe Nyembu; Gloire Mosala Telo; Christian Djuba Ngoy; Taty Msueun Sakobo; Joel Mbembo Massolo; Blandine Mbo Muyembe; Richard Kapela Mvwala; Cedric Kabemba Ilunga; Emmanuel Bakilo Limbole; Jeff Mukengeshay Ntalaja; Roger Minga Kongo
Journal:  PLoS One       Date:  2020-12-18       Impact factor: 3.240

4.  Characteristics and prognostic factors of COVID-19 among infected cases: a nationwide Tunisian analysis.

Authors:  Chahida Harizi; Ines Cherif; Nourhene Najar; Molka Osman; Rym Mallekh; Oumaima Ben Ayed; Yosr Ayedi; Sonia Dhaouadi; Aicha Hchaichi; Mouna Safer; Hejer Letaief; Ilhem Bouaziz; Sondes Derouiche; Donia Gharbi; Leila Bouabid; Souha Bougatef; Hamida Ben Salah; Radhouane Fakhfakh; Salma Abid; Ilhem Boutiba Ben Boubaker; Mohamed Kouni Chahed; Nissaf Bouafif Ben-Alaya
Journal:  BMC Infect Dis       Date:  2021-02-03       Impact factor: 3.090

5.  Patient characteristics associated with COVID-19 positivity and fatality in Nigeria: retrospective cohort study.

Authors:  Kelly Osezele Elimian; Chinwe Lucia Ochu; Blessing Ebhodaghe; Puja Myles; Emily E Crawford; Ehimario Igumbor; Winifred Ukponu; Adobola Olayinka; Olusola Aruna; Chioma Dan-Nwafor; Olatayo Ayodeji Olawepo; Oladipo Ogunbode; Rhoda Atteh; William Nwachukwu; Sudhir Venkatesan; Chijioke Obagha; Samuel Ngishe; Kabir Suleiman; Muhammad Usman; Hakeem Abiola Yusuff; Ifeoma Nwadiuto; Abbas Aliyu Mohammed; Rabi Usman; Nwando Mba; Olaolu Aderinola; Elsie Ilori; John Oladejo; Ibrahim Abubakar; Chikwe Ihekweazu
Journal:  BMJ Open       Date:  2020-12-17       Impact factor: 2.692

Review 6.  ACE2 imbalance as a key player for the poor outcomes in COVID-19 patients with age-related comorbidities - Role of gut microbiota dysbiosis.

Authors:  Sofia D Viana; Sara Nunes; Flávio Reis
Journal:  Ageing Res Rev       Date:  2020-07-16       Impact factor: 11.788

Review 7.  COVID-19 and diabetes mellitus: from pathophysiology to clinical management.

Authors:  Soo Lim; Jae Hyun Bae; Hyuk-Sang Kwon; Michael A Nauck
Journal:  Nat Rev Endocrinol       Date:  2020-11-13       Impact factor: 47.564

8.  Clinical management and mortality among COVID-19 cases in sub-Saharan Africa: A retrospective study from Burkina Faso and simulated case analysis.

Authors:  Laura Skrip; Karim Derra; Mikaila Kaboré; Navideh Noori; Adama Gansané; Innocent Valéa; Halidou Tinto; Bicaba W Brice; Mollie Van Gordon; Brittany Hagedorn; Hervé Hien; Benjamin M Althouse; Edward A Wenger; André Lin Ouédraogo
Journal:  Int J Infect Dis       Date:  2020-09-26       Impact factor: 3.623

9.  Use of subcutaneous tocilizumab in patients with COVID-19 pneumonia.

Authors:  Maria Mazzitelli; Eugenio Arrighi; Francesca Serapide; Maria Chiara Pelle; Bruno Tassone; Rosaria Lionello; Giuseppina Marrazzo; Domenico Laganà; Francesco Saverio Costanzo; Giovanni Matera; Enrico Maria Trecarichi; Carlo Torti
Journal:  J Med Virol       Date:  2020-09-30       Impact factor: 20.693

10.  Inflammation induced by influenza virus impairs human innate immune control of pneumococcus.

Authors:  Simon P Jochems; Fernando Marcon; Beatriz F Carniel; Mark Holloway; Elena Mitsi; Emma Smith; Jenna F Gritzfeld; Carla Solórzano; Jesús Reiné; Sherin Pojar; Elissavet Nikolaou; Esther L German; Angie Hyder-Wright; Helen Hill; Caz Hales; Wouter A A de Steenhuijsen Piters; Debby Bogaert; Hugh Adler; Seher Zaidi; Victoria Connor; Stephen B Gordon; Jamie Rylance; Helder I Nakaya; Daniela M Ferreira
Journal:  Nat Immunol       Date:  2018-10-29       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.